diphenhydramine has been researched along with Ovarian Neoplasms in 17 studies
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen." | 9.07 | Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy. ( Fanning, J; Hilgers, RD, 1994) |
| "In prospective alternative crossover test, we confirmed significant superiority of a three-drug combination of clonazepam (C) lorazepam (L) and dexamethasone (D) to (L) and (D) to control vomiting induced by 50 mg/m CDDP containing chemotherapy for gynecological malignancies (p less than 0." | 7.68 | [Evaluation of antiemetic effect of clonazepam, metoclopramide, dexamethasone and diphenhydramine for prevention of cisplatin-induced vomiting]. ( Asano, H; Hatae, M; Hokanishi, H; Mitsuo, M; Nakamura, Y; Onishi, Y; Sakurai, K, 1990) |
| "To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen." | 5.07 | Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy. ( Fanning, J; Hilgers, RD, 1994) |
| "Background Carboplatin-based chemotherapy offers high response rates and improved overall survival for women with epithelial ovarian cancer, but its use is limited by the occurrence of hypersensitivity reactions." | 3.88 | Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer. ( Bulter, M; Deghan Manshadi, S; Jerzak, KJ; Mackay, HJ; Maganti, M; McCuaig, JM; Ng, P; Oza, A, 2018) |
| "In prospective alternative crossover test, we confirmed significant superiority of a three-drug combination of clonazepam (C) lorazepam (L) and dexamethasone (D) to (L) and (D) to control vomiting induced by 50 mg/m CDDP containing chemotherapy for gynecological malignancies (p less than 0." | 3.68 | [Evaluation of antiemetic effect of clonazepam, metoclopramide, dexamethasone and diphenhydramine for prevention of cisplatin-induced vomiting]. ( Asano, H; Hatae, M; Hokanishi, H; Mitsuo, M; Nakamura, Y; Onishi, Y; Sakurai, K, 1990) |
| "Five patients with recurrent ovarian cancer who had a previous documented hypersensitivity reaction to carboplatin and a good clinical indication for continuing treatment with platinum were retreated following cisplatin desensitisation." | 2.71 | Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. ( Friedlander, M; Jones, R; Ryan, M, 2003) |
| "Paclitaxel 135 mg/m2 was infused as a single dose over 1 hour or was divided into three doses infused over 1 hour on 3 consecutive days." | 2.68 | One-hour paclitaxel infusion schedules: a phase I/II comparative trial. ( Greco, FA; Hainsworth, JD, 1995) |
| "paclitaxel in the management of ovarian cancer appears justified." | 2.67 | Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer. ( Barakat, R; Curtin, J; Francis, P; Hakes, T; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rowinsky, E; Rubin, S, 1994) |
| "Female patients with ovarian cancer are at high risk for emesis." | 2.67 | Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research. ( , 1994) |
| " Adverse events with grade 3 or above hematologic toxicity were oligochromemia (M: 24." | 1.32 | [Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration]. ( Fujii, T; Komatsu, M; Kumagai, M; Kusuda, T; Naitou, H; Shinkou, S; Takehara, K, 2004) |
| " When HSR was observed administration of paclitaxel was temporally stopped and before the re-challenge additional intravenous dosage of hydrocortisone (200-500 mg) and diphenhydramine (25 mg) was given." | 1.31 | [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma]. ( Emerich, J; Kobierski, J; Majdak, E; Mielcarek, P, 2002) |
| " One patient experienced a life-threatening adverse reaction within minutes of receiving the first dose." | 1.31 | Pegylated liposomal doxorubicin: tolerability and toxicity. ( Goram, AL; Richmond, PL, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Melnikova, M | 1 |
| Wauer, US | 1 |
| Mendus, D | 1 |
| Hilger, RA | 1 |
| Oliver, TG | 1 |
| Mercer, K | 1 |
| Gohlke, BO | 1 |
| Erdmann, K | 1 |
| Niederacher, D | 1 |
| Neubauer, H | 1 |
| Buderath, P | 1 |
| Wimberger, P | 1 |
| Kuhlmann, JD | 1 |
| Thomale, J | 1 |
| Jerzak, KJ | 1 |
| Deghan Manshadi, S | 1 |
| Ng, P | 1 |
| Maganti, M | 1 |
| McCuaig, JM | 1 |
| Bulter, M | 1 |
| Oza, A | 1 |
| Mackay, HJ | 1 |
| Jones, R | 1 |
| Ryan, M | 1 |
| Friedlander, M | 1 |
| Kobierski, J | 1 |
| Majdak, E | 1 |
| Mielcarek, P | 1 |
| Emerich, J | 1 |
| Kumagai, M | 1 |
| Fujii, T | 1 |
| Komatsu, M | 1 |
| Kusuda, T | 1 |
| Takehara, K | 1 |
| Shinkou, S | 1 |
| Naitou, H | 1 |
| Greco, FA | 2 |
| Hainsworth, JD | 2 |
| Markman, M | 1 |
| Francis, P | 1 |
| Rowinsky, E | 1 |
| Hakes, T | 1 |
| Reichman, B | 1 |
| Jones, W | 1 |
| Lewis, JL | 1 |
| Rubin, S | 1 |
| Curtin, J | 1 |
| Barakat, R | 1 |
| Fanning, J | 1 |
| Hilgers, RD | 1 |
| Chan, AT | 1 |
| Yeo, W | 1 |
| Leung, WT | 1 |
| Johnson, PJ | 1 |
| Myers, JS | 1 |
| Kearney, K | 1 |
| Moon, C | 1 |
| Verschraegen, CF | 1 |
| Bevers, M | 1 |
| Freedman, R | 1 |
| Kudelka, AP | 1 |
| Kavanagh, JJ | 1 |
| Goram, AL | 1 |
| Richmond, PL | 1 |
| Kwon, JS | 1 |
| Elit, L | 1 |
| Finn, M | 1 |
| Hirte, H | 1 |
| Mazurka, J | 1 |
| Moens, F | 1 |
| Trim, K | 1 |
| Hatae, M | 1 |
| Nakamura, Y | 1 |
| Mitsuo, M | 1 |
| Sakurai, K | 1 |
| Asano, H | 1 |
| Onishi, Y | 1 |
| Hokanishi, H | 1 |
| Wiernik, PH | 1 |
| Schwartz, EL | 1 |
| Strauman, JJ | 1 |
| Dutcher, JP | 1 |
| Lipton, RB | 1 |
| Paietta, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for diphenhydramine and Ovarian Neoplasms
| Article | Year |
|---|---|
Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Dexamethasone; Diphenhydramine; Drug Hypersensitivity | 2003 |
One-hour paclitaxel infusion schedules: a phase I/II comparative trial.
Topics: Blood Cell Count; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration | 1995 |
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.
Topics: Dexamethasone; Diphenhydramine; Drug Administration Schedule; Female; Humans; Injections, Intraperit | 1994 |
Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cimetidine; Dexamethasone; Diphenhydr | 1994 |
Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Diphenhydramine; Drug Combinations; Drug T | 1994 |
Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Diphenh | 1994 |
11 other studies available for diphenhydramine and Ovarian Neoplasms
| Article | Year |
|---|---|
Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Diphenhydramine; DNA Adducts | 2020 |
Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2018 |
[Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phyto | 2002 |
[Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dex | 2004 |
Thromboembolic events with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cerebral Infarction; Diphenhydramine; Female; H | 1996 |
Emergency. Chemotherapy-induced hypersensitivity reaction.
Topics: Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Diphenhydramine; Drug Hypersensitivity; Eme | 2000 |
Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma; Cimetidine; Cystadenocarcinoma; Dexamethasone; | 2000 |
Pegylated liposomal doxorubicin: tolerability and toxicity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphenhydram | 2001 |
A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Topics: Administration, Oral; Cohort Studies; Dexamethasone; Diphenhydramine; Drug Hypersensitivity; Female; | 2002 |
[Evaluation of antiemetic effect of clonazepam, metoclopramide, dexamethasone and diphenhydramine for prevention of cisplatin-induced vomiting].
Topics: Adult; Antiemetics; Cisplatin; Clonazepam; Dexamethasone; Diphenhydramine; Female; Humans; Metoclopr | 1990 |
Phase I clinical and pharmacokinetic study of taxol.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alkaloids; Alopecia; Cimetidine; Dexamethasone; Diph | 1987 |